Sentences with phrase «ovarian cancer patients who»

«New test could detect ovarian cancer patients who are strongly responding to treatment.»

Not exact matches

In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared with those given a placebo.

For instance, a plaintiff in the Supreme Court case, Ellen T. Matloff of Yale Cancer Center, said that in 2006 she knew of a patient who had had breast and ovarian cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York Cancer Center, said that in 2006 she knew of a patient who had had breast and ovarian cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York Times.

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves — despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

The researchers also are seeking other potential drug targets in the 50 percent of patients who don't have high levels of the anti-death protein, as well as biomarkers in addition to CA125 that could be used to screen for ovarian cancer.

«Once the ovarian cancer becomes drug resistant we can not cure it,» says Rodriguez a gynecologic oncologist who provides treatment to ovarian cancer patients and is director of the precision medicine initiative at Rutgers Cancer Institute of New Jcancer becomes drug resistant we can not cure it,» says Rodriguez a gynecologic oncologist who provides treatment to ovarian cancer patients and is director of the precision medicine initiative at Rutgers Cancer Institute of New Jcancer patients and is director of the precision medicine initiative at Rutgers Cancer Institute of New JCancer Institute of New Jersey.

The ENGOT - OV16 / NOVA trial evaluated the efficacy and safety of the PARP inhibitor niraparib as maintenance therapy in patients with recurrent ovarian cancer who respond to platinum - based chemotherapy.

Longer term, they want to quickly diagnose additional cancer types, including ovarian and pancreatic cancers, which are fast - spreading and require early detection for a patient to survive, says Goda, who was recently appointed as a chemistry professor at the University of Tokyo but will continue his research with U.C.L.A..

It has had particularly strong results in phase III trials in patients who inherited mutations to the BRCA genes, many of whom had breast or ovarian cancer.

He concluded: «Once it is approved by the regulatory authorities, I'll consider niraparib for all my patients with recurrent ovarian cancer who respond to platinum regardless of BRCA status.»

Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.

Patients with stage 2, 3, and 4 ovarian cancer who are in complete remission after first - line treatment;

The poor survival in advanced ovarian cancer is due both to late diagnosis, as well as to the lack of effective second - line therapy for patients who relapse.

In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).

Platinum - sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression - free survival.

Doctors often fail to recommend genetic testing for breast - cancer patients, even those who are at high risk for mutations linked to ovarian and other cancers, according to a study published Tuesday.

Coukos, who is currently leading an ovarian cancer clinical trial sponsored by CRI's Clinical Accelerator, sought to understand why PD - 1 / PD - L1 immunotherapies are often ineffective for these patients, even though ovarian tumors are often infiltrated by «killer» T cells that recognize tumor - specific neoantigens and express high levels of PD - 1.

ZEJULA is the first and only once - daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.1 - 3

ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.

Overholser and colleagues discuss the role of endocrine therapy to reduce risk for breast cancer, and cite interesting data from patients who developed premature ovarian failure due to ovarian irradiation or alkylating chemotherapeutic agents, which demonstrates that these patients were at decreased risk for developing subsequent breast cancer.

Research shows that hospitals that treat more than 20 ovarian cancer cases a year and surgeons who operate on more than 10 cases a year have significantly better patient outcomes than lower volume hospitals and surgeons, according to the Valley Health System.

We also work with oncologists and other doctors who understand the severity and life - risks for ovarian cancer patients.